Safety of intravenous thrombolysis for ischemic stroke in patients with hematologic malignancies: A single institution experience.

ABSTRACT:

Background

Data on safety of thrombolysis for acute ischemic stroke (AIS) in patients with hematologic malignancy is not well established. We report our single institution experience with thrombolysis in this patient population.

Methods

We identified patients with pathology-confirmed hematologic malignancy from 2000-2022. Primary exposure was presence of AIS and receipt of intravenous (IV) thrombolysis. Primary outcome was safety of IV thrombolysis in this patient population. Safety was measured through imaging review for hemorrhagic transformation, post-stroke mortality, and modified Rankin Scale (mRS) at 90 days.

Results

Among 45,894 patients with hematologic malignancy, 1,099 (2.4%) were identified as having a suspected AIS. Twenty (1.8%) received IV tissue plasmin

SUBMITTER: Rael S 

PROVIDER: S-EPMC10530002 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature